Zhimeng Biopharma

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
KCNQ2/3 (Kv7.2/7.3) potassium channel (opener)Small molecule
EpilepsyAmyotrophic Lateral Sclerosis
Phase 1
TLR8
Chronic Hepatitis B

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (2)
CB03-154Phase 2Focal Epilepsy
Est. primary completion 2027-09 · NCT06612775 · CT.gov ↗
What to watch
CB03-154Phase 2/3ALS (Amyotrophic Lateral Sclerosis)
Est. primary completion 2027-09-30 · NCT07082192 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
CB03-154Phase 2Focal Epilepsy
Est. primary completion 2029-01 · NCT07238868 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.